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background:  Patients with prior stroke are at greater risk for CV events post-ACS and may have a different risk/benefit profile when 
receiving oral anticoagulation in addition to antiplatelet therapy.
methods:  We studied 7391 patients with ACS from APPRAISE-2, stratified by the presence or absence of prior stroke. Baseline 
characteristics and outcomes of CV death, MI, or stroke were compared between groups. Interaction between treatment and outcomes 
were tested before and after multivariable adjustment with Cox proportional hazards models.
Results:  A total of 902 (12%) had prior stroke. Those with prior stroke were older (median 69 vs 67 yrs), had more hypertension (91% vs 
77%), PVD (22% vs18%), and impaired renal function (38% vs 30%) but less diabetes (44% vs 48%). Patients with prior stroke had higher 
unadjusted rates of CV death, MI, or stroke over a median of 240 (132, 352) days of follow-up. In those with prior stroke, apixaban was 
associated with a numerically higher risk of CV death, MI, or stroke, compared with placebo (HR 1.34; 95% CI 0.93-2.10); apixaban was 
not associated with worse clinical outcomes than placebo in those without prior stroke (HR 0.87; 95% CI 0.73-1.04) (interaction p=0.037).
conclusion:  Post-ACS, patients with prior stroke are at greater risk for CV events and may have a differential risk/benefit profile with oral 
anticoagulation. Further investigation is needed to understand the mechanism(s) and determine the optimal antithrombotic therapy for post-
ACS patients with prior stroke.
 
